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Objective. Preclinical studies suggest a role for
lysophosphatidic acid (LPA) in the pathogenesis of sys-
temic sclerosis (SSc). We undertook this study to assess
SAR100842, a potent selective oral antagonist of the LPA1
receptor, for safety, biomarkers, and clinical efficacy in
patients with diffuse cutaneous SSc (dcSSc).
Methods. An 8-week double-blind, randomized,
placebo-controlled study followed by a 16-week open-label
extension with SAR100842 was performed in patients
with early dcSSc who had a baseline modified Rodnan
skin thickness score (MRSS) of at least 15. The primary
end point was safety during the double-blind phase of the
trial. Exploratory end points included the identification
of an LPA-induced gene signature in patients’ skin.
Results. Seventeen of 32 patients were randomly
assigned to receive placebo and 15 to receive SAR100842;
30 patients participated in the open-label extension study.
The most frequent adverse events reported for SAR
100842 during the blinded phase were headache, diar-
rhea, nausea, and falling, and the safety profile was
acceptable during the open-label extension. At week 8,
the reduction in MRSS was numerically greater in the
SAR100842 group than in the placebo group (mean  SD
change 3.57  4.18 versus 2.76  4.85; treatment
effect 1.2 [95% confidence interval 4.37, 2.02]; P =
0.46). A greater reduction of LPA-related genes was
observed in skin samples from the SAR100842 group at
week 8, indicating LPA1 target engagement.
Conclusion. SAR100842, a selective orally avail-
able LPA1 receptor antagonist, was well tolerated in
patients with dcSSc. The MRSS improved during the
study although the difference was not significant, and
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additional gene signature analysis suggested target en-
gagement. These results need to be confirmed in a larger
controlled trial.
Systemic sclerosis (SSc) is characterized by fibro-
sis of the skin and internal organs, prominent alterations
of the microvasculature, and frequent abnormalities of
cellular and humoral immunity (1). SSc is an orphan dis-
ease with high morbidity, which strongly impairs the
quality of life, and it has a high case-specific mortality
(2). The high burden of severe skin and internal organ
involvement in the early stages of diffuse cutaneous SSc
(dcSSc) has been highlighted by many cohort studies.
Safe and effective treatments for skin and other mani-
festations of dcSSc are lacking (3).
The pathogenesis of SSc is complex, and at present
there is no unifying theory that may explain all its aspects.
There is consensus that early vascular events associated
with autoimmunity and inflammation lead to fibroblast
activation and differentiation, promoting subsequent fibro-
sis. A broad range of biologic processes interact in SSc, and
these include involvement of key profibrotic cytokines and
growth factors, an imbalance in Th1/Th2/Th17/Treg cell
systems promoting inflammation and fibrosis, and activa-
tion of B cells promoting production of autoantibodies (1).
Lysophosphatidic acid (LPA) is a lipid mediator
that signals through specific G protein–coupled receptors,
designated LPA1 through LPA6. It is generated at sites of
inflammation or cell injury by the action of lysophospholi-
pase D, also known as autotaxin, on lysophosphatidylcho-
line and other lysophospholipids (4). LPA exerts various
physiologic effects on the receptors of parenchymal cells
with some tissue specificities with regard to the various
receptors (5–7). LPA mediates a variety of cell activities,
including mitogenesis, cell differentiation, cell survival,
cytoskeletal reorganization, cell migration, and extracellu-
lar matrix production. Recent studies of circulating
markers, in vitro cell activation, or animal models have
suggested that LPA is involved, and plays an important
role, in the pathogenesis of SSc. The role of LPA has also
been demonstrated in several animal models of organ
fibrosis independently of SSc (8–11).
SAR100842 is a potent selective LPA1 receptor
antagonist (Sanofi R&D). In vivo, SAR100842 reversed
dermal thickening and significantly inhibited myofibroblast
differentiation and reduced collagen content in a mouse
model of skin fibrosis. Similar antifibrotic properties were
observed using the Tsk1 mouse model (Illiano S, et al:
unpublished observations). Mechanistic investigations
showed that the antifibrotic effects of LPA1 blockade could
be mediated partly via inhibition of the Wnt signaling
pathway. Taking into account the promise of LPA1 recep-
tor blockade in preclinical models of fibrosis and the
unmet need of patients with early dcSSc, we performed a
randomized proof of biologic activity study assessing the
effects of SAR100842 in patients with early dcSSc.
PATIENTS AND METHODS
Study design. This was a double-blind, randomized, pla-
cebo-controlled, 8-week phase IIa study followed by an open-
label extension study for 16 weeks (see Supplementary Figure 1,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40547/abstract). The ob-
jective was to investigate the effects of orally administered
SAR100842 in patients with dcSSc, characterizing safety as well
as plasma pharmacokinetics and pharmacodynamics, with a
focus on clinical efficacy and on SSc-related biomarkers. In the
double-blind phase of the study, SAR100842 at 300 mg or
matching placebo was administered orally twice a day (in the
treatment arm, patients received 100 mg plus 200 mg tablets of
SAR100842 twice daily for a total daily dose of 600 mg). Follow-
ing a screening period of up to 14 days, eligible patients were
randomized. Clinical and biologic parameters were assessed,
and skin biopsy samples were obtained from a predefined area
of the forearm at baseline and end of treatment (week 8).
Patients who had completed the 8-week treatment and
who did not meet any discontinuation criteria (see Amended
Clinical Trial Protocol 5, http://onlinelibrary.wiley.com/doi/10.
1002/art.40547/abstract) were invited to participate in the open-
label noncontrolled 16-week extension phase of the study with
the same dosage of SAR100842 as in the initial part of the trial.
Patients were evaluated at the end of the extension phase (week
24) for clinical and biologic assessments including 2 additional
skin biopsies in those who consented.
The dose of 300 mg twice a day was selected for the study
based on activity/efficacy data from in vitro pharmacology models
and in vivo animal disease models as well as on the safety profile
observed in healthy volunteers (Illiano S, et al: unpublished
observations). The duration of 8 weeks was chosen based on
expert opinion, which suggested that an 8-week treatment dura-
tion would be sufficient to demonstrate significant changes in
SSc-related biomarkers. This design reduced the exposure of
dcSSc patients to an experimental drug in this phase IIa study,
while it provided the necessary data on safety and activity to sup-
port full development of the drug. A total of 12 active clinical
sites located in Switzerland, France, the UK, Italy, and the US
participated in this study.
Patients. Patients met the 1980 American College of
Rheumatology (ACR) preliminary classification criteria for SSc
(12), with diffuse cutaneous involvement according to the cri-
teria of LeRoy et al (13), and had disease duration of less than
36 months since the onset of the first SSc manifestation other
than Raynaud’s phenomenon. Other key inclusion criteria were
a baseline modified Rodnan skin thickness score (MRSS) ≥15
of 51 (14) together with an area of definite involvement of the
mid-volar forearm allowing 4-mm skin biopsy samples.
Immunosuppressive therapies stable for 4 weeks prior
to enrollment were permitted including prednisolone up to 10
mg/day, methotrexate up to 25 mg/week, azathioprine up to
100 mg/day, and mycophenolate mofetil up to 2 gm/day (for
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exclusion criteria for medication dosages, see Amended Clini-
cal Trial Protocol 5, http://onlinelibrary.wiley.com/doi/10.1002/
art.40547/abstract). We excluded patients experiencing ortho-
static hypotension (postural reduction of systolic blood pres-
sure by >20 mm Hg or reduction of diastolic blood pressure by
>10 mm Hg), moderate-to-severe postural dizziness, or presyn-
cope or syncope within the last 6 months of screening. These
exclusion criteria were related to the current knowledge of the
study drug obtained in phase I studies.
Study end points. The primary end point was safety and
tolerability during the 8-week treatment period. Secondary end
points were change from baseline to week 8 in skin and blood
biomarkers, changes from baseline to week 8 in the MRSS and
Scleroderma Health Assessment Questionnaire (SHAQ) (15),
safety and tolerability during the extension treatment period,
and pharmacokinetics. Skin biopsy samples were used for RNA
extraction, and some messenger RNA (mRNA) biomarkers
were assessed using quantitative reverse transcription–polymer-
ase chain reaction (qRT-PCR), including cartilage oligomeric
matrix protein (COMP), thrombospondin 1 (TSP-1), plasmino-
gen activator inhibitor 1, Wnt-2, and secreted Frizzled-related
protein 4 (sFRP-4). Other skin biopsy samples were dedicated to
immunohistochemistry. Labeling for a-smooth muscle actin
(a-SMA) was performed on serial slides, and skin thickness (his-
tology) was evaluated. LPA markers were selected based on liter-
ature data and internal confirmation using dermal fibroblasts
from SSc patients treated with LPA. The choice of other markers
(COMP, TSP-1, type I collagen, and a-SMA) was based on liter-
ature data selecting genes or proteins that may play a key role in
the evolution of fibrosis in SSc patients (16,17).
To explore the effect of SAR100842 on the LPA pathway,
we used the results of a parallel study performed using cultured
dermal fibroblasts from patients with SSc. LPA gene expression
response was defined in the cultured dermal fibroblasts study.
This LPA response was used in combination with the expression
profile in patient skin biopsy samples for identifying an LPA sig-
nature, according to a guided clustering algorithm. The goal of
using this data integration approach was to ensure that the identi-
fied gene cluster with high LPA treatment response was also con-
sistently expressed and correlated in skin biopsy samples. The
identified fibroblast LPA signature was subsequently reduced to a
single composite biomarker called the pathway activation index
(PAI), computed as the coefficient of a robust regression on the
expression matrix of the LPA signature at each treatment visit
(median polish algorithm) (18). The PAI was then used as a surro-
gate biomarker for investigating SAR100842 treatment response.
Exploratory end points were change from baseline to week 24 on
the MRSS and SHAQ, and also the change in pain or pruritus
from baseline to week 8 and week 24.
Statistical analysis. Sample size determination. No for-
mal sample size calculation was performed for this proof of bio-
logic activity study, and the sample size for the study was based
on empirical considerations.
Safety analyses. The safety analyses were based on the
safety population of all randomized patients who actually
received at least 1 dose of the investigational medicinal product,
and they were performed according to the treatment actually
received in the core or extension phases of the study. The safety
analyses were descriptive.
Efficacy analyses. The efficacy analyses were based on the
modified intent-to-treat (ITT) population, which included all ran-
domized patients who had actually received at least 1 dose of the
investigational medicinal product and who had undergone at least
1 measurement after administration of the investigational medici-
nal product during the blinded period of the study (the double-
blind phase). The modified ITT population for the open-label
extension phase included all randomized patients who did actually
receive at least 1 dose of the investigational medicinal product
during the open-label extension phase and who had undergone at
least 1 measurement after administration of the investigational
medicinal product during the open-label extension phase.
An analysis of covariance (ANCOVA) was performed
for the total MRSS and the Health Assessment Questionnaire
disability index (HAQ DI) score (19) on the change from base-
line to week 8 in the modified ITT population, with treatment
group as the main factor and the baseline MRSS and HAQ DI
scores centered on their means in the modified ITT population
as a continuous covariate. Student’s t-test was used to deter-
mine the superiority of 300 mg SAR100842 twice a day over
placebo at week 8, with a nominal 2-sided Type I error rate of
5%. The analysis of other SHAQ variables was purely descrip-
tive. All other secondary end points were described by treat-
ment and analyzed within an ANCOVA.
Biomarker analyses. The biomarker analyses were based
on the population of all randomized and treated patients who
received at least 4 weeks of study drug with at least a baseline
and a postbaseline assessment. Prior to all statistical analyses,
mRNA data were normalized. Each biomarker was analyzed
using descriptive statistics. For each of the skin biomarkers
related to the disease (i.e., COMP, TSP-1, and type I collagen
mRNAs and a-SMA [16]), the change from baseline to week 8
measurement was analyzed using a rank ANCOVA, with treat-
ment group as fixed effect and baseline value as covariate.
Target engagement. SSc fibroblasts were prepared from
forearm biopsy samples following established outgrowth conditions
and were cultured in Ham’s F-12 medium with 10% heat-inacti-
vated fetal calf serum, 100 units/ml penicillin, 100 lg/ml strepto-
mycin, and 0.3 mg/ml L-glutamine. Dermal fibroblasts from 4
healthy volunteers and 10 SSc patients were seeded and treated
with vehicle or LPA at 10 lM for 24 hours. Supernatants were
removed and cells were rinsed and stored, and total RNA was
purified using an RNeasy Mini kit (Qiagen). The same methodol-
ogy was used to extract RNA from skin biopsy samples from
patients in Sanofi study no. ACT12339. Gene expression was mea-
sured by whole transcriptome profiling analysis using Affymetrix
GeneChip Human Genome U133 Plus 2.0 arrays. From each array
result, a probe cell intensity data file was computed, which repre-
sented an individual gene expression profile. Samples were clus-
tered based on Euclidean distance and correlation for evaluating
the similarity of the quality of each array to the quality of the other
arrays. We performed principal components analysis on expression
data as well as on quality control metrics of the raw data provided
by the Affymetrix platform (R-package simpleaffy; https://rdrr.io/
bioc/simpleaffy/).
The guided clustering algorithm (18) was used for the
identification of a set of genes that had high LPA perturbation in
the cell culture study and that were consistently expressed in the
skin biopsy samples from patients with SSc. A logistic regression
model was computed for each probe set separately, with the
LPA treatment label as the outcome variable (LPA = 1, placebo
= 0) and the probe set as the independent variable. Each model
was adjusted by fibroblast type (normal/SSc). The coefficient of
the probe set in the model was used as the LPA activation
strength for weighting the probe sets. The obtained weights were
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used in conjunction with the expression profile in skin biopsy
samples at baseline to extract the LPA signature. The LPA signa-
ture was condensed into 1 surrogate marker called the PAI.
Descriptive statistics of change in the LPA PAI from baseline to
the end of the 8-week treatment period were computed by treat-
ment arm. The difference between SAR100842 and placebo was
investigated using the following equation:
DPAImain part ¼ b0 þ b1  treatmentþ b2  PAIscaled baseline þ n
where b0 is the mean effect, b1 is the treatment effect, b2 is
the PAI value effect at baseline, and n represents residuals
from the model. Targeted gene expression analysis of selected
LPA-related and fibrosis genes was carried out in the same
skin biopsy samples using qRT-PCR.
Ethics approval. The protocol and its amendments were
submitted to independent ethics committees and/or institutional
review boards for review and written approval. All patients pro-
vided written informed consent prior to the conduct of any
study-related procedures, and the optional skin biopsy informed
consent form was obtained from patients who agreed to the col-
lection of skin biopsy samples. In addition, dermal fibroblasts
were grown from skin biopsy samples obtained from another
cohort of SSc patients fulfilling the ACR/European League
Against Rheumatism 2013 classification criteria (20). The pro-
cedure was approved by the local ethics committee (University
of Naples), and patients signed informed consent forms.
RESULTS
Baseline characteristics of the patients, flow of
enrollment into the study, discontinuations, and compli-
ance. Of 48 patients screened, 16 (33.3%) were deter-
mined to be ineligible. Thirty-two patients were
randomized into the study; for a period of 8 weeks, 15
received 300 mg SAR100842 twice a day and 17 received
placebo twice a day. Patients in each group had compara-
ble demographic characteristics at baseline, consistent
with the overall population of dcSSc patients (Table 1).
One patient receiving SAR100842 discontinued
treatment on personal request but was included in the
modified ITTanalysis. Of the 32 patients initially random-
ized to the double-blind phase, 30 were enrolled into the
open-label extension phase (16 initially treated with pla-
cebo and 14 initially treated with SAR100842). One
patient in the placebo/SAR100842 group and 1 patient in
the SAR100842/SAR100842 group requested to discon-
tinue treatment due to adverse events (AEs). The mean
overall compliance was comparably high between treat-
ment groups (99.6% in the placebo group versus 98.5% in
the SAR100842 group).







Age, mean  SD years 50.6  11.3 48.8  10.3 49.8  10.7
Female 12 (71) 9 (60) 21 (66)
Caucasian/white 13 (76) 13 (87) 26 (81)
Weight, mean  SD kg 70.6  16.8 75.1  19.3 72.7  17.9
Current smoker 3 (18) 2 (13) 5 (16)
Disease duration, mean  SD months 19.6  7.4 20.4  8.9 20.0  8.0
Raynaud’s phenomenon 17 (100) 14 (93) 31 (97)
Digital ulcers (past or current) 6 (35) 4 (27) 10 (31)
Joint synovitis 5 (29) 4 (27) 9 (28)
Tendon friction rubs 6 (35) 7 (47) 13 (41)
Renal crisis 1 (6) 0 1 (3)
Dyspnea (significant) 7 (41) 2 (13) 9 (28)
Fibrosis on plain radiograph 3 (18) 1 (7) 4 (13)
ACA positive 1 (6) 0 1 (3)
Anti–Scl-70 positive 5 (29) 4 (27) 9 (28)
Anti–RNA polymerase III positive 4 (24) 8 (53) 12 (38)
MRSS
Mean  SD 24.8  7.8 22.7  8.2 23.8  7.9
Median (range) 23 (15–38) 21 (15–44) 22 (15–44)
HAQ DI score
Mean  SD 1.27  0.75 1.23  0.77 1.25  0.75
Median (range) 1.25 (0.0–2.5) 1.38 (0.0–2.4) 1.37 (0.0–2.5)
Previous immunosuppressive or steroid
medications
14 (82) 10 (67) 24 (75)
Mycophenolate mofetil 5 (29) 7 (47) 12 (38)
Methotrexate 9 (53) 1 (7) 10 (31)
Systemic steroids 8 (47) 6 (40) 14 (44)
Topical steroids 1 (6) 1 (7) 2 (6)
* Except where indicated otherwise, values are the number (%). ACA = anticentromere antibody;
MRSS = modified Rodnan skin thickness score; HAQ DI = Health Assessment Questionnaire disability
index.
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Good safety and tolerability of SAR100842. Over-
all, SAR100842 was well tolerated. AEs are described in
Supplementary Table 1, http://onlinelibrary.wiley.com/doi/
10.1002/art.40547/abstract. Eighty percent of patients in
the SAR100842 group versus 71% of patients in the pla-
cebo group reported at least 1 treatment-emergent AE.
However, most treatment-emergent AEs were mild to
moderate in intensity. There was 1 treatment-emergent
serious AE (SAE) in the SAR100842 group (syncope) in
a patient with a medical history of syncope in childhood.
In the open-label extension phase, 2 patients reported a
treatment-emergent SAE, 1 in each group. Dyspnea was
reported in 1 patient 6 days after switching from placebo
to SAR100842, and this was considered to be related to
the investigational medicinal product, while an infected
digital ulcer in another patient was not considered to be
drug-related. Two patients discontinued prematurely due
to treatment-emergent AEs, 1 for moderate arthritis in
the SAR100842/SAR100842 group and 1 for pruritus,
skin discoloration, and facial swelling in the placebo/
SAR100842 group. With regard to the laboratory safety
assessments, no safety concern emerged from the various
laboratory parameters (see Supplementary Table 2, http://
onlinelibrary.wiley.com/doi/10.1002/art.40547/abstract).
Efficacy as determined by change in MRSS during
the controlled and extension phases. A primary analysis
was conducted in the modified ITT population on patients
who were treated until week 8. There was a numerically
greater decrease from baseline in the total MRSS in the
SAR100842 group compared to the placebo group, al-
though the difference did not reach statistical significance
(mean  SD change 3.57  4.18 versus 2.76  4.85;
treatment effect 1.2 [95% confidence interval {95% CI}
4.37, 2.02]; P = 0.46) (median change 4.00 [inter-
quartile range {IQR} 5, 1] versus 1.00 [IQR 5, 0],
respectively) (Figure 1).
After 24 weeks of treatment, patients in the SAR
100842/SAR100842 group experienced a clinically meaning-
ful decrease in total MRSS versus baseline (mean  SD
change 7.36  4.24; median change 7.50), and a high
percentage (78.6%) of patients improved by at least 5 points
(the definition of responders). Patients initially receiving 8
weeks of placebo also demonstrated an improvement in
MRSS after 24 weeks (mean  SD change 7.31  4.59;
median change from baseline 7.00), with a responder rate
of 69.2%.
Changes in quality of life during controlled and
extension phases. There was no statistically significant
difference between the SAR100842 and placebo groups
in change in HAQ DI total score from baseline to week
8 (mean  SD change 0.00  0.33 in the placebo group
versus 0.14  0.30 in the SAR100842 group; treatment
effect 0.1 [95% CI 0.38, 0.09]). However, it should
be pointed out that the mean absolute difference from
baseline observed in the SAR100842 group (0.14) was
clinically meaningful; indeed, a HAQ DI score improve-
ment of ≥0.14 is considered to be the minimum clinically
important difference in patients with SSc. In contrast to
the improvement between baseline and week 8, the
improvement seen in the mean HAQ DI total score was
clinically meaningful from baseline to week 24 in both
the placebo/SAR100842 group and the SAR100842/
SAR100842 group (mean  SD change 0.23  0.30
versus 0.15  0.33, respectively), and the percentages
of patients whose HAQ DI total scores decreased by ≥
0.14 were comparable in the 2 groups.
Effects on pruritus and pain during controlled and
extension phases. Based on the preclinical rationale, LPA
receptor antagonists may be effective against pruritus.
Interestingly, despite a low baseline value, there was
numerical improvement in the SAR100842 group and
worsening in the placebo group (mean  SD change
0.37  3.92 versus 0.25  1.79) in the severity of pruritus
assessed by patients from baseline to week 8 using a 0–10-
cm visual analog scale. Similarly, reduced pruritus severity
was observed in SAR100842/SAR100842-treated patients
compared to placebo/SAR100842-treated patients (mean
 SD change 1.38  2.85 versus 0.84  1.67). Com-
pared to week 8, the severity of pruritus was further
decreased at week 24 in patients initially treated with
SAR100842 or placebo. The severity of pain assessed by
Figure 1. Change in modified Rodnan skin thickness score (MRSS)
from baseline to week 8 in the modified intent-to-treat population.
Data are presented as box plots, where the boxes represent the 25th
to 75th percentiles, the lines within the boxes represent the median,
and the lines outside the boxes represent the 10th and 90th per-
centiles. Circles indicate outliers.
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patients using a numerical pain scale was low at baseline in
the study population, and no conclusion could be drawn.
No significant differences between groups in skin
and blood biomarker end points. There was no statisti-
cally significant differential expression of any skin mRNA
and protein biomarkers or blood protein biomarkers
between placebo- and SAR100842-treated patients. Type
I collagen and a-SMA were used as fibrosis markers and
were not modulated by SAR100842 treatment (Figure 2).
Disease signature was evaluated using either the 4-gene
biomarker as described by Farina et al (16) or a combina-
tion of TSP-1 and COMP. No changes in these genes were
correlated with change in MRSS (Table 2). However,
after 8 weeks there was a trend toward a reduction in
TSP-1 with SAR100842 compared to placebo, although
this did not reach statistical significance (Figure 3). We
also evaluated the gene for membrane-spanning 4
domains, subfamily A, member 4A (a marker of M2-type
macrophages). The expression of this marker, such as in
the 2-gene signature (17), was not modulated by SAR
100842 and was not correlated with the change in MRSS
(not shown).
Global change in gene expression in skin samples
at 8 weeks between vehicle- and SAR100842-treated
patients was evaluated using a stringent cutoff for false
discovery rate (P = 0.05) or less stringent criteria (P =
0.1). No significant difference was observed under any
conditions. Data obtained using a cutoff for a false dis-
covery rate of <0.1 are presented in Supplementary
Table 3, http://onlinelibrary.wiley.com/doi/10.1002/art.405
47/abstract.
SAR100842 induces target engagement in the LPA
pathway. There was a nonsignificant numerical reduction
from baseline in some LPA pathway biomarkers (plasmin-
ogen activator inhibitor 1, Wnt-2, and sFRP-4) in SAR
100842-treated patients compared to placebo-treated
patients (Figure 4). Although the decrease in these
biomarkers was not significant, it is of interest since they
have been shown to be regulated by LPA and SAR100842
in dermal fibroblasts from SSc patients. Thus, a post hoc
analysis was performed to identify a more global LPA sig-
nature in SSc dermal fibroblasts and skin biopsy samples
and to evaluate the impact of SAR100842 on this signa-
ture in patient skin to assess target engagement.
The signature was identified using both microarray
data obtained in SSc dermal fibroblasts treated for 24
hours with LPA and microarray data from skin biopsy
samples from SSc patients at baseline. A guided cluster-
ing method was performed to give weight to genes that
were expressed at a significant level following LPA treat-
ment but that were also expressed at a significant level in
skin biopsy samples. This led to a list of 47 genes identi-
fied as an LPA signature (see Supplementary Table 4,
http://onlinelibrary.wiley.com/doi/10.1002/art.40547/abstract).
This signature reflects pathways such as those for prolif-
eration and epidermal growth factor signaling, which are
known to be mechanistically part of LPA responses in
other cell types. These genes were reduced to a unique
surrogate biomarker in 1 dimension called the PAI,
using the median polish algorithm (21). The PAI was
extracted as a row effect as it represents the summary
expression in each patient. A significant decrease in the
Table 2. Absence of correlation of change in 4 gene biomarkers
with change in MRSS*
Gene
Correlation of change in





* MRSS = modified Rodnan skin thickness score.
Figure 2. Changes in the skin fibrosis markers a-smooth muscle actin (a-SMA) and type I collagen from baseline to week 8. Data are presented
as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the
boxes represent the 10th and 90th percentiles. Circles indicate outliers.
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PAI was observed in the SAR100842 group (P = 0.0089)
(Figure 5).
DISCUSSION
LPA is a phospholipid growth factor that targets
cells through a number of cell surface receptors, and it
has been implicated in the pathogenesis of SSc. Of great-
est interest, it appears that it may contribute to excessive
tissue fibrosis, mainly through LPA1 receptor activation
(5), as observed in SSc. Recent findings further empha-
size the key roles of autotaxin and the LPA axis in SSc
(22). SAR100842 is a low molecular weight, selective
inhibitor of the LPA1 receptor that is being developed as
a potential novel therapy for SSc with the aim of
reducing or even reversing the progression of fibrosis.
This phase IIa study is the first to assess oral administra-
tion of SAR100842 in patients with early dcSSc. The
safety and tolerability of SAR100842 was the primary
outcome measure, and SAR100842 was shown to be well
tolerated in patients with dcSSc.
In preclinical studies, the administration of SAR
100842 to rats at doses up to 2,000 mg/kg/day caused no
toxicologically relevant effects. Findings related to the
compound were limited to a slightly higher incidence of
regurgitation in females at a high dose, and the present
study did not show any specific gastrointestinal AEs in
SSc patients. In previous phase I studies, the safety profile
was very good, and overall the most frequently reported
SAR100842-related AEs were headache, symptomatic
orthostatic hypotension or postural dizziness, and flatu-
lence. Those AEs were not severe or serious. In the pres-
ent study, both in the short-term double-blind phase and
in the longer term open-label extension phase, no safety
signals emerged regarding vital signs, orthostatic hypoten-
sion, electrocardiography, or laboratory parameters. A
common toxicologic concern with antifibrotic agents is
whether patients may exhibit a delay in normal wound
healing. Studies with LPA receptor antagonists using inci-
sional and excisional wounding in rats have been reassuring
(22), but it is noteworthy that in the present study,
although one-third of patients had digital ulcerations at
Figure 3. Changes from baseline to week 8 in 4 gene biomarkers of skin fibrosis. Data are presented as box plots, where the boxes represent the
25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th percentiles.
Circles indicate outliers.
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baseline, no overt safety concerns emerged for them,
confirming the good safety profile in SSc patients.
The clinical efficacy of SAR100842 was part of the
secondary end points, but no effect was expected on the
MRSS after 8 weeks of treatment because the MRSS is
slow in changing. Nevertheless, at the end of the double-
blind period, a numerically greater decrease in total
MRSS score from baseline in the SAR100842 group com-
pared to the placebo group was detected without reaching
statistical significance (treatment effect 1.2 [95% CI
4.37, 2.02]; median change 4.00 versus 1.00, respec-
tively). Also, there was a numerically greater reduction
without reaching statistical significance in the HAQ DI
score in the SAR100842 group (treatment effect 0.1
[95% CI 0.38, 0.09]). These findings are promising; they
might be due to the mechanism of action of SAR100842
and/or they might also be explained by a large proportion
of subjects receiving background immunosuppressive
medications. These findings were supportive of the effect
observed after 24 weeks of treatment, when patients expe-
rienced a clinically meaningful decrease in total MRSS
Figure 4. Changes from baseline to week 8 in lysophosphatidic acid pathway markers. Data are presented as box plots, where the boxes represent
the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th per-
centiles. Circles indicate outliers.
Figure 5. Change in the pathway activation index (PAI) from baseline
to week 8. Data are presented as box plots, where the boxes repre-
sent the 25th to 75th percentiles, the lines within the boxes represent
the median, and the lines outside the boxes represent the 10th and
90th percentiles. Circles indicate outliers.
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(median change 7.50) and a high percentage of them
(78.6%) improved by at least 5 points from baseline (re-
sponders) (23); similar benefit was observed in the HAQ
DI score. Although these were secondary end points and
had weak statistical power, the size of the decreases must
be noted and is larger than that observed in other trials
targeting the same SSc population. Furthermore, the
similar trend observed for skin changes and quality of life
is encouraging and promising for future trials. Neverthe-
less, and despite being encouraging, the open-label data
should be interpreted with caution.
This study must be interpreted while taking its lim-
itations into account. The sample size was not large but
was consistent with the design of a proof of biologic activ-
ity study looking primarily at safety. The duration may be
considered short, and most trials are expected to last
more than 6 months, but the observed changes in MRSS
in this population are promising. SSc is a systemic disease
and organ involvement defines the prognosis. No data
could be provided on organ involvement from the present
study, and this will have to be addressed in the future.
Pharmacodynamic and biomarker assessments were
part of the secondary end points. There was no statistically
significant differential expression of any biomarker be-
tween the 2 groups of patients.
Using a new unbiased statistical analysis, a guided
clustering algorithm allowed the identification of a set of
genes that had high LPA perturbation in the cell culture
study and that were consistently expressed and corre-
lated with similar expression in skin samples from
patients. This LPA signature was then reduced to 1 di-
mension, and change in the resulting PAI was computed
in skin biopsy samples from patients treated with placebo
versus patients treated with SAR100842. A significant
effect of SAR100842 on change from baseline in the PAI
was indicative of an effect of SAR100842 on the LPA
signature (15 patients per treatment arm), demonstrat-
ing target engagement upon SAR100842 treatment for 8
weeks.
The optimal clinical trial duration for patients with
SSc is still unknown. Some observations regarding colla-
gen metabolism suggest that a clinical trial duration of 24
weeks or longer might be recommended. Indeed, in the
phase II tocilizumab data (24), the 2-gene biomarker was
able to differentiate tocilizumab from placebo at 24
weeks. The biomarkers in clinical trials of SSc have been
shown to correlate with skin fibrosis (as seen here) rather
than to predict skin progression. In addition, the collagen
turnover (which is a product of collagen production and
collagen degradation) may require several weeks to be
modulated, and this also depends on whether the pharma-
cologic agent directly (e.g., knockout) or indirectly (the
current inhibitor) targets collagen products. A longer ver-
sion of this trial with clinical and biologic outcome mea-
sures at 4–6 months might have shown statistically
significant differences.
This study demonstrates that LPA1 blockade by
SAR100842 is well tolerated in patients with early dcSSc.
The results show target engagement with SAR100842 as
well as some promising clinical and biologic changes. Nev-
ertheless, treatment effect cannot be inferred from skin
fibrosis biomarkers, but these biomarkers may be informa-
tive as shown in other recent trials (24–26). Taken to-
gether, these results suggest the potential clinical benefit
of SAR100842 in dcSSc patients with unmet needs (27),
and SAR100842 deserves evaluation in confirmatory trials.
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